Core One Labs Announces Breakthrough in Solving Psilocybin Dosing Problems by Introducing Biosynthetic Psilocybin to its Patented Thinstrip Delivery Method


Ryan Allway

January 12th, 2021

Psychedelics


Core One Labs Inc. (CSE:  COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”) is pleased to  announce its plans to initiate another intellectual property strategy that will utilize its  patented transmucosal thinstrip delivery method (“thinstrip delivery method”) in  combination with its proprietary biosynthetic psilocybin, developed by its wholly-owned  subsidiary, Vocan Biotechnologies Inc. (“Vocan”).

The Company’s existing thinstrip delivery method has been patented for use with THC  and CBD (CannaStripsTM) and has the potential for use with all naturally occurring  compounds, including psilocybin

Through cutting-edge research by the Company’s team at Vocan, a cost effective method  for producing biosynthesized psilocybin has been developed. This low cost method of  psilocybin production, in combination with the incorporation of psilocybin into the  Company’s thinstrip technology, will result in an innovative and first-to-market delivery  method of psilocybin for medical purposes.

Core One’s objective in developing the psilocybin thinstrips is to assist with the delivery  of revolutionary psychedelic treatment methods to address mental health conditions such  as depression, anxiety and addictions.

Methods of accurate dosing and effective delivery of psilocybin have gone relatively  under-researched, and current methods utilized by companies using traditional oral  delivery methods can cause hallucinations, digestive issues, and inaccurate dosages  resulting in undesired side effects. The Company’s patented sublingual transmucosal  (orally dissolvable) thinstrip technology, for the delivery of psilocybin, will aim to address  these issues, and anticipates the provision of many potential advantages and benefits  such as the rapid dissolving and onset of action to the bloodstream, as well as  concentration control and time released dosing. Thinstrip delivery technology is a natural,  non-toxic, biodegradable, biocompatible composite, which is user friendly. The sublingual  polymer thinstrip, with nano particulated active ingredients, skips the digestive system  and is absorbed directly into the bloodstream through the membranes in the mouth, resulting in optimum bioavailability (absorption percentage) of the active ingredients.  Direct delivery to the bloodstream means that dosages can be less potent with the same  affect.

According to the World Health Organization, almost 350 million people worldwide were  affected by depression in 2016. Common antidepressant drugs help maintain the balance  of various hormones and chemicals in the brain which assists in the treatment of  depression.

The Center for Disease Control and Prevention (CDC), reported that the percentage of  people above the age of 12 years using antidepressants in the U.S. rose 12.7% in 2011- 2014. According to MedGadget, the antidepressant drug market was valued at $13.69  billion in 2018 and is expected to reach $15.88 billion by 2025. The CDC said that in the  U.S., antidepressants were the most commonly prescribed drugs in 2013 and from over  16 million long term users, around 70% are female.

“One of the critical issues surrounding the use of psilocybin is accurate dosing in oral  delivery methods. Our breakthrough technology is a game changer in the psychedelic  space and has the potential to revolutionize the way patients receive psychedelics as  medicine and reduce over concentrations and resulting adverse effects.” stated Dr.  Robert E.W. Hancock, Executive Chairman of the Company.

About Core One Labs Inc.  

Core One Labs Inc. is a research and technology company focused in life sciences and  on bringing psychedelic medicines to market through novel delivery systems and  psychedelic assisted psychotherapy. The Company has developed a patent pending thin  film oral strip (the “technology”) which dissolves instantly when placed in the mouth and  delivers organic molecules in precise quantities to the bloodstream, maintaining excellent  bioavailability. With this technology, the Company intends to further develop its  technology to focus on delivering psychedelic molecules with an initial focus on  psilocybin. Core One also holds an interest in walk-in medical clinics which maintain a  database of over 200,000 patients combined. Through research and development in  these clinics, including the integration of its intellectual property related to psychedelic  treatments and novel drug therapies, the Company intends to work towards regulatory  approval for research that advances psychedelic-derived treatments for mental health  disorders.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading